ArticleMed (New York, N.Y.)2026

Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanoma.

Lilit Karapetyan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.